Galderma Group AG (CH:GALD)

:GALD

GALD

Galderma Group AG

RESEARCH TOOLSreports

Want to see CH:GALD full AI Analyst Report?

Galderma Group AG (GALD) Price & Analysis

13 Followers

GALD Stock Chart & Stats

CHF156.85

-CHF8.02(-7.15%)

At close: Mar 06 4:00 PM EST

CHF156.85

-CHF8.02(-7.15%)

Day’s Range― - ―

52-Week RangeCHF76.10 - CHF170.10

Previous CloseN/A

Volume230.69K

Average Volume (3M)337.59K

Market Cap

CHF36.77B

Enterprise ValueCHF37.78B

Total Cash (Recent Filing)CHF780.00M

Total Debt (Recent Filing)CHF2.75B

Price to Earnings (P/E)28.6

Beta0.74

Next Earnings

Jul 23, 2026

EPS Estimate

1.77

Next Dividend Ex-DateN/A

Dividend Yield0.09%

Share Statistics

EPS (TTM)1.58

Shares Outstanding237,897,630

10 Day Avg. Volume210,266

30 Day Avg. Volume337,589

Financial Highlights & Ratios

PEG Ratio0.61

Price to Book (P/B)4.71

Price to Sales (P/S)8.88

P/FCF Ratio37.24

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF188.00

Price Target Upside19.86% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)4.59

Revenue Forecast (FY)CHF6.27B

Bulls Say, Bears Say

Bulls Say

Drug CommercialisationAnalyst highlights Nemluvio's strong clinical profile in pediatric atopic dermatitis and an accelerating sales ramp, supporting expectations for significantly higher peak sales and prompting analyst price-target upgrades.

Financial Performance And GuidanceBroad-based net sales growth, improved core profitability and a stronger balance sheet with lower leverage enhance financial flexibility to fund launches and support upgraded multi-year revenue and margin targets.

Product Approvals And Market ExpansionFDA approval of Restylane Contour for temple hollowing broadens the injectable portfolio's clinical uses and should increase adoption for treatments addressing volume loss linked to medication-driven weight loss.

Bears Say

Policy RiskIntroduction of U.S. tariffs on patented drugs increases policy uncertainty that could pressure pricing and margins despite available exemptions and inventory measures.

Revenue OutlookAnalyst expectation that sales will be broadly in line with consensus implies limited revenue upside and reduces the chance of a re-rating driven by surprising financial beats.

Segment UnderperformanceModest weakness in the Derma Skincare division acted as a headwind to overall growth and could weigh on consensus forecasts if the segment does not regain momentum.

Galderma Group AG News

Capitalizing on Emerging Aesthetic Demand: Galderma’s Menopause and GLP‑1 Weight Loss Opportunity Supports Reiterated Buy Rating

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Galderma Group AG,...

13d ago

Galderma Group AG: Buy Rating on Resilient Demand, Growth Catalysts, and Undervalued Long-Term Cash Generation

Goldman Sachs analyst Aron Adamski has reiterated their bullish stance on GALD stock, giving a Buy rating today....

15d ago

Sustained Growth and Favorable Risk‑Reward in Injectable Aesthetics Underpin Galderma Buy Rating

Benjamin Jackson CFA, an analyst from Jefferies, maintained the Buy rating on Galderma Group AG. The associated price...

25d ago

Galderma: Restylane Contour Label Expansion Strengthens Aesthetics Leadership and Supports Buy Rating

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Galderma Group AG and keeping the price...

30d ago

Hold Rating Maintained as Supportive FY26 Guidance Offers Limited Upside Versus High Expectations and Valuation

Morgan Stanley analyst Thibault Boutherin maintained a Hold rating on Galderma Group AG today and set a price...

2M ago

Buy Rating Backed by Strong Q4 Performance, Upgraded Nemluvio Outlook, and Enhanced 2026 Guidance Upside

Analyst Benjamin Jackson CFA from Jefferies maintained a Buy rating on Galderma Group AG and keeping the price...

2M ago

Buy Rating on Galderma: Leading Global Skin‑Health Platform with Diversified Growth and Undervalued Upside

Galderma Group AG (GALD) has received a new Buy rating, initiated by H.C. Wainwright analyst, Ram Selvaraju. Ram...

2M ago

Galderma Buy Rating Underpinned by Strengthened CFO Leadership and Strategic Growth Prospects

Galderma Group AG, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Benjamin Jackson...

2M ago

Galderma Group AG: Buy Rating Driven by Underappreciated Nemluvio Peak Sales and Pipeline Upside

Benjamin Jackson CFA, an analyst from Jefferies, maintained the Buy rating on Galderma Group AG. The associated price...

3M ago

Galderma Group AG: Buy Rating Reaffirmed with 19% Price Target Increase Amid Strong Nemluvio Growth Projections

Analyst Benjamin Jackson CFA from Jefferies maintained a Buy rating on Galderma Group AG and increased the price...

4M ago

GALD FAQ

What was Galderma Group AG’s price range in the past 12 months?

Galderma Group AG lowest stock price was CHF76.10 and its highest was CHF170.10 in the past 12 months.

What is Galderma Group AG’s market cap?

Galderma Group AG’s market cap is CHF36.77B.

When is Galderma Group AG’s upcoming earnings report date?

Galderma Group AG’s upcoming earnings report date is Jul 23, 2026 which is in 91 days.

How were Galderma Group AG’s earnings last quarter?

Galderma Group AG released its earnings results on Mar 05, 2026. The company reported CHF1.584 earnings per share for the quarter, beating the consensus estimate of CHF1.23 by CHF0.354.

Is Galderma Group AG overvalued?

According to Wall Street analysts Galderma Group AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Galderma Group AG pay dividends?

Galderma Group AG pays a Notavailable dividend of CHF0.15 which represents an annual dividend yield of 0.09%. See more information on Galderma Group AG dividends here

What is Galderma Group AG’s EPS estimate?

Galderma Group AG’s EPS estimate is 1.77.

How many shares outstanding does Galderma Group AG have?

Galderma Group AG has 237,897,630 shares outstanding.

What happened to Galderma Group AG’s price movement after its last earnings report?

Galderma Group AG reported an EPS of CHF1.584 in its last earnings report, beating expectations of CHF1.23. Following the earnings report the stock price went up 6.975%.

Which hedge fund is a major shareholder of Galderma Group AG?

Currently, no hedge funds are holding shares in CH:GALD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Galderma Group AG

Galderma Group AG is engaged in cosmetic industry. Its segment includes Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.

Galderma Group AG (GALD) Earnings & Revenues

Historic Earnings Reports

GALD Stock 12 Month Forecast

Average Price Target

CHF188.00

▲(19.86% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"94":"CHF94","261":"CHF261","135.75":"CHF135.8","177.5":"CHF177.5","219.25":"CHF219.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":260,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF260.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":188,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF188.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":155,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF155.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[94,135.75,177.5,219.25,261],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,156.4,164.36923076923077,172.33846153846153,180.30769230769232,188.27692307692308,196.24615384615385,204.2153846153846,212.18461538461537,220.15384615384616,228.12307692307692,236.09230769230768,244.06153846153848,252.03076923076924,{"y":260,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,156.4,158.83076923076925,161.26153846153846,163.6923076923077,166.12307692307692,168.55384615384617,170.98461538461538,173.41538461538462,175.84615384615384,178.27692307692308,180.7076923076923,183.13846153846154,185.56923076923076,{"y":188,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,156.4,156.2923076923077,156.1846153846154,156.0769230769231,155.96923076923076,155.86153846153846,155.75384615384615,155.64615384615385,155.53846153846155,155.43076923076924,155.3230769230769,155.2153846153846,155.1076923076923,{"y":155,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":95.27,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162.1,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >